口腔黏膜炎治疗市场 - 按治疗类型、药物类别、配销通路、最终用途和预测，2024 年至 2032 年

由于癌症发生率上升以及对有效治疗的需求增加，口腔黏膜炎治疗市场规模预计从 2024 年到 2032 年复合年增长率将达到 7.1%。医疗保健当局正在审查和批准新的治疗方法，以解决接受化疗和放射治疗的癌症患者口腔黏膜炎的盛行率。

监管机构正在促进创新疗法的批准，以减轻癌症患者的症状并提高其生活品质。不断加强研究力度，重点开发有针对性的、更有效的治疗方法，以利用医学科学技术的进步，将促进产业成长。例如，2023 年 2 月，美国 FDA 授予 Avasopasem 治疗相关口腔黏膜炎的优先审查资格，承认其作为先进疗法在解决化疗对癌症患者口腔健康不利影响方面的潜力。

整个市场分为治疗类型、药物类别、配销通路、最终用途和地区。

就治疗类型而言，漱口水领域的口腔黏膜炎治疗市场预计从 2024 年至 2032 年将录得显着的复合年增长率。由抗菌剂和舒缓剂等成分配製而成的漱口水有助于缓解正在接受癌症治疗的患者的症状。漱口水配方的进步导致新型化合物或靶向输送系统的整合，以提高治疗期间的功效和舒适度。

按配销通路，在线药房领域的口腔粘膜炎治疗行业规模预计将在2024 年至2032 年期间上升。支持性护理产品的机会。这些平台还使患者能够浏览各种治疗方法，包括漱口水和其他专门用于缓解黏膜炎症状的口腔护理产品。

从区域来看，在不断提高口腔黏膜炎治疗有效性和可及性的技术创新的推动下，亚太地区口腔黏膜炎治疗市场规模预计将在 2024 年至 2032 年间呈现强劲增长。积极探索先进的漱口水配方和标靶输送系统等创新，以改善症状缓解和患者舒适度，促进区域产业的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 癌症盛行率增加
    • 提高对支持性护理的认识和关注
    • 癌症治疗方式的技术进步
  • 产业陷阱与挑战
    • 治疗费用高
    • 现有治疗方法疗效有限
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析
• 未来市场趋势

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按治疗类型，2021 - 2032 年

• 主要趋势
• 止痛药
• 漱口水
• 其他治疗类型

第 6 章：市场估计与预测：按药物类别，2021 - 2032 年

• 主要趋势
• 消炎剂
• 抗菌剂
• 抗真菌剂
• 抗肿瘤
• 抗生素
• 其他药物类别

第 7 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药房
• 网路药房

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 医院和诊所
• 门诊手术中心
• 其他最终用户

第 9 章：市场估计与预测：按地区划分，2021 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Amgen Inc.
• Basic Pharma Life Science Pvt Ltd.
• CANbridge Pharmaceuticals Inc.
• Enzychem Lifesciences Corporation
• EpicentRx, Inc.
• Galera Therapeutics, Inc.
• Helsinn Healthcare SA.
• Innovation Pharmaceuticals Inc.
• Monopar Therapeutics, Inc.
• Pfizer Inc.
• Soleva Pharma, LLC.
• Swedish Orphan Biovitrum AB

Oral Mucositis Treatment Market size is projected to record 7.1% CAGR from 2024 to 2032, driven by the rising rate of cancer along with the increased demand for effective therapies. Healthcare authorities are reviewing and approving new treatment methods to address the prevalence of oral mucositis among cancer patients undergoing chemotherapy and radiation therapy.

Regulatory agencies are facilitating the approval of innovative therapies for alleviating symptoms and improving the quality of life for cancer patients. Rising research efforts to focus on developing targeted and more efficacious treatment for leveraging advances in medical science and technology will boost the industry growth. For instance, in February 2023, the U.S. FDA granted Priority Review to Avasopasem for treatment-related oral mucositis for recognizing its potential as an advanced therapy in addressing the adverse effects of chemotherapy on oral health in cancer patients.

The overall market is segregated into treatment type, drug class, distribution channel, end-use, and region.

In terms of treatment type, the oral mucositis treatment market from the mouthwash segment is expected to record significant CAGR from 2024 to 2032. Mouthwash helps in soothing and managing symptoms, such as mouth pain and inflammation. Mouthwashes formulated with ingredients like antimicrobials and soothing agents are assisting in providing relief to patients undergoing cancer treatments. Advancements in mouthwash formulations are leading to the integration of novel compounds or targeted delivery systems to enhance efficacy and comfort during treatment.

By distribution channel, the oral mucositis treatment industry size from the online pharmacy segment is projected to rise from 2024 to 2032. Online pharmacies are offering convenience and accessibility for purchasing oral mucositis treatments for providing patients with easy access to medications and supportive care products. These platforms are also enabling patients to browse a variety of treatments including mouthwashes and other oral care products specifically designed to alleviate symptoms of mucositis.

Regionally, the Asia Pacific oral mucositis treatment market size is projected to exhibit robust growth between 2024 and 2032, fueled by the ongoing technological innovations for enhancing the effectiveness and accessibility of treatments for managing oral mucositis. Innovations, such as advanced mouthwash formulations and targeted delivery systems are actively explored to improve symptom relief and patient comfort, adding to the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cancer
    • 3.2.1.2 Growing awareness and focus on supportive care
    • 3.2.1.3 Technological advancements in cancer treatment modalities
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatments
    • 3.2.2.2 Limited efficacy of existing treatments
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis
• 3.7 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Pain control medication
• 5.3 Mouthwash
• 5.4 Other treatment types

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Anti-inflammatory
• 6.3 Antimicrobials
• 6.4 Antifungal
• 6.5 Anti-neoplastic
• 6.6 Antibiotics
• 6.7 Other drug classes

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Ambulatory surgical centers
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Amgen Inc.
• 10.2 Basic Pharma Life Science Pvt Ltd.
• 10.3 CANbridge Pharmaceuticals Inc.
• 10.4 Enzychem Lifesciences Corporation
• 10.5 EpicentRx, Inc.
• 10.6 Galera Therapeutics, Inc.
• 10.7 Helsinn Healthcare SA.
• 10.8 Innovation Pharmaceuticals Inc.
• 10.9 Monopar Therapeutics, Inc.
• 10.10 Pfizer Inc.
• 10.11 Soleva Pharma, LLC.
• 10.12 Swedish Orphan Biovitrum AB